KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Convertible Debt: 2009-2025

Historic Convertible Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $567.1 million.

  • Ionis Pharmaceuticals' Convertible Debt fell 9.66% to $567.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.1 million, marking a year-over-year decrease of 9.66%. This contributed to the annual value of $628.5 million for FY2024, which is 0.50% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Convertible Debt stood at $567.1 million for Q3 2025, which was up 0.12% from $566.4 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Convertible Debt ranged from a high of $629.3 million in Q1 2025 and a low of $540.7 million during Q1 2021.
  • Its 3-year average for Convertible Debt is $615.4 million, with a median of $625.4 million in 2023.
  • In the last 5 years, Ionis Pharmaceuticals' Convertible Debt surged by 38.69% in 2021 and then decreased by 9.66% in 2025.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Convertible Debt stood at $619.1 million in 2021, then increased by 0.50% to $622.2 million in 2022, then increased by 0.50% to $625.4 million in 2023, then climbed by 0.50% to $628.5 million in 2024, then declined by 9.66% to $567.1 million in 2025.
  • Its Convertible Debt stands at $567.1 million for Q3 2025, versus $566.4 million for Q2 2025 and $629.3 million for Q1 2025.